Patently innovative how pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs
Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regula...
| Autor principal: | |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Oxford :
Biohealthcare : Woodhead Pub
2012.
|
| Edición: | 1st edition |
| Colección: | Woodhead Publishing series in biomedicine ;
no. 64. |
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009628059406719 |
Tabla de Contenidos:
- Cover; Dedication; Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs; Copyright; Contents; Acknowledgements; List of figures and tables; List of abbreviations; About the author; 1 Introduction; 1.1 The emergence of global pharmaceutical linkage; 1.2 Canadian pharmaceutical linkage regulations; 1.3 Organization; Notes; 2 Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy; 2.1 Drug approval; 2.2 Patents; 2.3 Linkage regulations; 2.4 IPR rights and innovation policy; Notes
- 3 Empirical analysis of drug approval3.1 Introduction; 3.2 Analysis; 3.3 Results; 3.4 Discussion; 3.5 Interpretation of data; 3.6 Study limitations; 3.7 Assessing the lifecycle approach: the long view; 3.8 Government as representative public agent; 3.9 Summary and conclusions; Notes; 4 Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage; 4.1 Introduction; 4.2 Methods; 4.3 Results; 4.4 Discussion; Notes; 5 Empirical analysis of drug patenting in multiple high-value cohorts; 5.1 Introduction; 5.2 Methods; 5.3 Results; 5.4 Discussion
- 5.5 Summary and conclusionsNotes; 6 Implications of empirical data: are pharmaceutical linkage regulations a success?; 6.1 Introduction; 6.2 Debate preceding Bill C-91; 6.3 'Original policy intent'; 6.4 'Patent-specific' analysis; 6.5 Statutory interpretation; 6.6 Revisiting the empirical data; 6.7 Summary and conclusions; Notes; 7 Future directions: testable hypotheses and evolution toward global pharmaceutical linkage; 7.1 Hypotheses regarding cluster-based drug development; 7.2 Globalization of pharmaceutical linkage; Notes; Index
